Viatris Inc has received a notable update regarding its shareholder structure, as Davis Selected Advisers has filed to report an increase in its stake in the company. This change is significant as it reflects ongoing investment interest in the pharmaceutical preparations sector.

According to the recent filing, Davis Selected Advisers now holds 72,403,329 shares of Viatris, which represents approximately 6.3% of the company. This increase in ownership could potentially influence future corporate governance and strategic decisions within Viatris.

Background

Viatris Inc is a prominent player in the pharmaceutical industry, classified under the SIC code 2834 for Pharmaceutical Preparations. The company trades on the Nasdaq under the ticker symbol VTRS. Viatris was formed through the merger of Mylan and Upjohn, a division of Pfizer, and has been active in the market since its inception.

What the Filing Says

The filing, dated November 6, 2026, indicates that Davis Selected Advisers has beneficially owned a total of 72,403,329 shares, with 70,080,338 shares providing sole voting power. The report states, "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business..." This suggests that the shares were not acquired for the purpose of influencing control over Viatris.

Impact

This update may affect various stakeholders, including current shareholders, management, and potential investors. The increased stake by Davis Selected Advisers could lead to greater scrutiny of Viatris's corporate strategies and governance practices.

What's Next

The filing does not say what happens next.